Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials
Open Access
- 10 October 2024
- journal article
- Published by Elsevier in The Lancet
- Vol. 404 (10461) , 1407-1418
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK (A27691)
- Medical Research Council (C8225/A21133)
- Medical Research Council (PRCRPG-Nov21\\100001)
This publication has 21 references indexed in Scilit:
- The Lancet Breast Cancer CommissionThe Lancet, 2024
- Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trialsThe Lancet, 2023
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trialsThe Lancet, 2019
- Breast Cancer Screening for Women at Average RiskJAMA, 2015
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trialsThe Lancet, 2015
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trialsThe Lancet, 2015
- The Will Rogers phenomenon in the staging of breast cancer – Does it matter?Cancer Epidemiology, 2015
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trialsThe Lancet, 2011
- Floating absolute risk: An alternative to relative risk in survival and case‐control analysis avoiding an arbitrary reference groupStatistics in Medicine, 1991